Immuneering Q3 2026 earnings

IMRX · 2026-10-29 16:12 AMC ET · 8-K on SEC · 10-Q on SEC

Net loss widened to $24.2 million ($0.37 per share) as R&D expenses increased to $20.7 million, while cash position declined to $166.1 million.

Headline numbers

not stated in the 8-K

Revenue breakdown

not stated in the 8-K

Margins and costs

  • Gross margin not stated in the 8-K
  • Operating expenses $25.8 million (+67.4% YoY)
  • One-offs in the quarter not stated in the 8-K
  • Effective tax rate not stated in the 8-K
  • Non-GAAP bridge not stated in the 8-K

KPIs

MetricActualPrior quarterPrior yearChange
Cash runwayQ4 2028Q4 2028——
MAPKeeper 301 enrollment570 patients510 patients—+60 patients

Guidance

MetricGuidePrior guideChange
Cash runwayQ4 2028Q4 2028—
MAPKeeper 301 topline dataMid-2028Mid-2028—

What drove it

  • Revenue story No revenue reported.
  • EPS story Net loss per share widened due to higher operating expenses and a larger share count.
  • One-off check not stated in the 8-K

The good

  • Interest income increased to $1.2 million (+189.6% YoY).

The bad

  • Net loss widened to $24.2 million (+61.8% YoY).
  • R&D expenses increased to $20.7 million (+90.4% YoY).
  • Cash position declined to $166.1 million (-23.4% YoY).

The ugly

  • none

Open questions

  • What specific clinical costs drove the 90.4% increase in R&D expenses?
  • What caused the 11.2% sequential increase in interest income?
Full release

Earnings: IMRX — filed 2026-10-29

Immuneering Corp (IMRX) · Form 8-K, Item 2.02 · Filed · SEC filing

Immuneering Reports Third Quarter 2026 Financial Results and Provides Business Updates

- Phase 2 pancreatic cancer follow-up extended as patients on atebimetinib combinations live longer than projected -

- Updated Phase 2 atebimetinib + mGnP pancreatic cancer data (N=55) expected in the first half of 2027 -

- Phase 3 MAPKeeper 301 enrollment ahead of schedule; enrollment target expanding from 510 to 570 patients; potential to accelerate current mid-2028 topline data guidance -

NEW YORK, NY,

October 29, 2026

- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today reported financial results for the third quarter ended September 30, 2026, and provided business updates.

“We are thrilled to share that follow-up in our Phase 2 trial in first-line pancreatic cancer is being extended because patients are living longer than projected. We now plan to provide an update on topline data from the atebimetinib + mGnP arm of that trial in the first half of 2027. We are also excited to report that enrollment in our pivotal Phase 3 MAPKeeper 301 trial is ahead of schedule. This strong momentum enables us to expand the enrollment target and potentially accelerate our expected mid-2028 topline data readout. We have updated our cash runway guidance to the fourth quarter of 2028 to reflect our Phase 2 extension, accelerated and expanded Phase 3 enrollment, and commercial readiness activities,” said Ben Zeskind, Ph.D., CEO of Immuneering. “We are seeing growing recognition within the medical community of atebimetinib’s differentiated mechanism of action as demonstrated by the strong engagement with our presentations at recent medical meetings, including the 2026 AACR Conference on Pancreatic Cancer and ESMO Congress 2026. The 17.3 months median overall survival with excellent tolerability that we reported at ASCO is unprecedented among agents targeting this pathway, and we are excited to share updated clinical data in the first half of 2027.”

Corporate Highlights

• Phase 2 Pancreatic Cancer Trial Extended; Topline Data Update Expected in 1H 2027.

The Company plans to share further data from the mGnP arm of its Phase 2 PDAC trial (N = 55) in 1H 2027. Follow-up has been extended as patients are living longer than projected.

• Phase 3 MAPKeeper 301 Enrollment Updated.

Enrollment is ahead of schedule for Immuneering’s Phase 3 MAPKeeper 301 trial, enabling the Company to expand the trial to approximately 570 patients and potentially accelerate its current mid-2028 topline data readout guidance.

• Publication in

Cancer Research

Detailed Atebimetinib’s Unique Attributes as the First/Only Third Generation MEK Inhibitor, Including Broad, Durable Preclinical Activity and Favorable Tolerability Across RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition

In October, atebimetinib was featured on the cover of Cancer Research in a paper entitled “

Dual-MEK Inhibitor Atebimetinib Displays Broad Activity in RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition and Resisting RAF Bypass” and also described in a spotlight commentary entitled “MEKing Room: On the Quest for New Sources of Therapeutic Index in RAS/MAPK-Driven Cancers” both highlighting the Company’s publication in the same issue, which included data showing broad antitumor activity across KRAS-, NRAS-, and BRAF-mutant models, including colorectal, lung, and melanoma, by counteracting the RAF-mediated bypass signaling that has constrained other MEK inhibitors.

• Presented Data at the 2026 AACR Conference on Pancreatic Cancer Supporting Atebimetinib’s Mechanisms Designed to Extend Survival in Pancreatic Cancer.

In September, the Company presented data showing that stable or increased weight was twice as common among pancreatic cancer patients in an atebimetinib + mGnP trial, compared to those in a benchmark study, and that patients with stable or increased weight at three months had significantly longer overall survival than patients who lost weight at three months.

• Presented MAPKeeper 301 Trial Design at ESMO Congress 2026.

In October, Immuneering presented the design for its pivotal Phase 3 trial evaluating atebimetinib in combination with modified gemcitabine/nab-paclitaxel versus standard-of-care chemotherapy in first-line metastatic pancreatic cancer at ESMO.

Near-Term Milestone Expectations

Immuneering is planning for several near-term anticipated milestones, including:

• 4Q 2026 (SITC):

Preclinical data for atebimetinib in combination with anti-PD-1 in lung cancer to be shared at the Society for Immunotherapy of Cancer (SITC) Annual Meeting.

• 4Q 2026:

Dose the first patient in Phase 2 trial of atebimetinib + anti-PD-1 (cemiplimab) in lung cancer, with a preliminary data readout expected in late-2027.

• 1H 2027:

Updated 1L PDAC Phase 2 atebimetinib + mGnP data (N=55).

• Mid-2027:

Begin IND-enabling studies for our next DCI product candidate program.

• Late-2027:

Preliminary data readout expected from Phase 2 trial of atebimetinib + anti-PD-1 (cemiplimab) in lung cancer.

• Mid-2028:

Topline data readout from the MAPKeeper 301 trial.

Third Quarter 2026 Financial Highlights

Cash Position:

Cash, cash equivalents and marketable securities as of September 30, 2026 were $166.1 million, compared with $217.0 million as of December 31, 2025.

Research and Development (R&D) Expenses:

R&D expenses for the third quarter of 2026 were $20.7 million, compared with $10.9 million for the third quarter of 2025. The increase in R&D expenses was primarily attributable to higher clinical costs related to the Company’s lead program and increased personnel to support ongoing research and development activities.

General and Administrative (G&A) Expenses:... (truncated)e Company’s stock-based compensation costs and employee-related costs in connection with general and administrative functions.

Net Loss:

Net loss attributable to common stockholders was $24.2 million, or $0.37 per share, for the third quarter ended September 30, 2026, compared to $15.0 million, or $0.38 per share, for the third quarter ended September 30, 2025.

Financial Guidance

Based on cash, cash equivalents and marketable securities as of September 30, 2026, and current operating plans, the Company expects its cash runway to be sufficient to fund operations into the fourth quarter of 2028. The updated cash runway reflects the Phase 2 trial extension, accelerated and expanded Phase 3 enrollment, and commercial readiness activities.

About Immuneering Corporation

Immuneering is a late-stage clinical oncology company dedicated to keeping cancer patients alive and helping them thrive, with an initial focus on patients with RAS, RAF, and other MAPK-driven cancers. The Company is developing an entirely new category of cancer medicines, Deep Cyclic Inhibitors, designed to improve overall survival by three mechanisms: shrinking tumors durably with less resistance, preserving body mass by countering cachexia, and minimizing side effects to maximize performance status and combinability. Immuneering’s lead product candidate, atebimetinib, is an oral, once-daily Deep Cyclic Inhibitor of MEK, designed to improve survival across many cancer indications. The Company is conducting a global randomized pivotal trial, MAPKeeper 301, evaluating atebimetinib in combination with chemotherapy in first-line pancreatic cancer patients. The Company’s development pipeline also includes additional combination opportunities and preclinical stage programs. For more information, please visit www.immuneering.com.

Financial statements

Income Statement

Three Months Ended September 30, — (Unaudited)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Operating expenses
Research and development20,721,24310,867,98345,363,11232,793,835
General and administrative5,059,4594,505,40614,738,39812,807,465
Amortization of intangible asset7,3177,31721,95021,950
Total operating expenses25,788,01915,380,70660,123,46045,623,250
Loss from operations-25,788,019-15,380,706-60,123,460-45,623,250
Other income (expense)
Interest income1,204,598415,8313,647,7861,178,362
Other income, net390,8381,551,769
Net loss-24,192,583-14,964,875-54,923,905-44,444,888
Net loss per share attributable to common stockholders, basic and diluted-0.37-0.38-0.85-1.2
Weighted-average common shares outstanding, basic and diluted64,714,19439,670,09564,690,27537,077,041
Other comprehensive loss:
Unrealized loss from marketable securities-142,913-630,485
Comprehensive Loss-24,335,496-14,964,875-55,554,390-44,444,888

Balance Sheet

September 30, 2026 — (Unaudited)

September 30, 2026December 31, 2025
Current assets:
Cash and cash equivalents58,226,805128,645,025
Marketable securities87,178,64544,186,244
Prepaids and other current assets5,305,1543,414,685
Total current assets150,710,604176,245,954
Marketable securities, non-current20,712,25344,183,186
Property and equipment, net808,952938,481
Goodwill6,690,4316,690,431
Intangible asset, net299,197321,147
Right-of-use assets3,039,7833,322,249
Other assets299,827283,562
Total assets182,561,047231,985,010
Current liabilities:
Accounts payable2,758,2191,542,737
Accrued expenses7,498,1377,842,367
Other liabilities89,419291,513
Lease liabilities445,496397,104
Total current liabilities10,791,27110,073,721
Long-term liabilities:
Lease liabilities, net of current portion3,089,0793,427,321
Total liabilities13,880,35013,501,042
Stockholders’ equity:
Class A common stock, $0.001 par value, 200,000,000 shares authorized at September 30, 2026 and December 31, 2025; 64,763,155 and 64,648,230 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively64,76364,648
Additional paid-in capital504,409,076498,658,072
Accumulated other comprehensive income (loss)-549,15381,332
Accumulated deficit-335,243,989-280,320,084
Total stockholders' equity168,680,697218,483,968
Total liabilities and stockholders' equity182,561,047231,985,010

Cash Flow

From the 10-Q · Nine Months Ended September 30, — (Unaudited)

Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Cash flows from operating activities:
Net loss-54,923,905-44,444,888
Adjustments to reconcile to net loss to net cash used in operating activities:
Depreciation and amortization expense251,983248,628
Reduction in carrying amount of right-of-use assets282,466255,660
Intangible asset amortization21,95021,950
Stock-based compensation expense5,325,5764,673,290
Net accretion of discount on marketable securities-1,343,376
(Increase) decrease in:
Prepaid expenses and other current assets-1,697,8301,904,097
Other assets-16,265802,848
Increase (decrease) in:
Accounts payable1,215,482-474,214
Accrued expenses-344,2291,908,736
Lease liabilities-289,849-246,528
Other liabilities-202,094-153,576
Net cash used in operating activities-51,720,091-35,503,997
Cash flows from investing activities:
Purchases of property and equipment-122,455-18,316
Purchases of marketable securities-84,176,216
Maturities of marketable securities65,175,000
Net cash used in investing activities-19,123,671-18,316
Cash flows from financing activities:
Proceeds from exercise of stock options108,080138,700
Proceeds from issuance of common stock under employee stock purchase plan317,462421,910
Proceeds from issuance of common stock under at-the-market offering, net of issuance costs15,020,046
Proceeds from sale of common stock, prefunded warrants and common stock warrants through private placement24,998,919
Proceeds from public offering of common stock, net of commissions and underwriting164,500,006

Forward-Looking Statements

This press release contains forward-looking statements, including within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding: the treatment potential of atebimetinib, alone or in combination with other agents to treat cancer, including modified Gemcitabine/nab-paclitaxel (mGnP) in first-line pancreatic cancer and its potential to deliver overall survival with both durability and tolerability; expansion of the enrollment target enabling the Company to maintain or potentially accelerate the timing of the Phase 3 topline readout of the MAPKeeper 301 trial in mid-2028; the timing of a data update in the Phase 2a atebimetinib + mGnP trial in first-line pancreatic cancer; the timing of dosing and preliminary readout of the planned Phase 2 lung cancer trial; the timing of beginning IND-enabling studies in a second DCI program; our operating plans and anticipated cash runway, and the potential ability of the three design mechanisms of atebimetinib to shrink tumors durably, improve overall survival and overcome the limitations of conventional MAPK inhibition and provide a more sustained clinical benefit for patients.

These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: we are a late-stage clinical oncology company with a limited operating history and have not completed any registrational clinical trials; we have incurred significant losses, are not currently profitable and may never become profitable; limitations on our cash runway and potential increases in expenditures; our need for additional funding; our unproven approach to therapeutic intervention; our ability to address regulatory questions and changing regulatory standards, and the uncertainties relating to regulatory filings, reviews and approvals; the lengthy, expensive, and uncertain process of clinical drug development, including the uncertainty of whether positive preclinical or early clinical efficacy and safety results are confirmed in later-stage trials, potential delays in activation of trial sites or enrollment of trial participants, or failure to obtain regulatory approvals; our reliance on third parties and collaborators to conduct our clinical trials, manufacture our product candidates, and develop and commercialize our product candidates, if approved; failure to compete successfully against other drug companies; protection of our proprietary technology and the confidentiality of our trade secrets; potential lawsuits for, or claims of, infringement of third-party intellectual property or challenges to the ownership of our intellectual property; our patents being found invalid or unenforceable; costs and resources of operating as a public company; and unfavorable or no analyst research or reports.

These and other important factors discussed under the caption “Risk Factors” in our Quarterly Report on Form 10-Q for the period ended September 30, 2026, and our other reports filed with the U.S. Securities and Exchange Commission, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release..vestor Contact:

Laurence Watts

New Street Investor Relations laurence@newstreetir.com

Media Contact:

David Caouette dcaouette@immuneering.com

Earlier releases

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.